Last reviewed · How we verify
Reproductive Health Training Center of the Republic of Moldova — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Medical abortion | Medical abortion | marketed | Progesterone receptor antagonist + prostaglandin analog combination | Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP) | Reproductive Health / Obstetrics |
Therapeutic area mix
- Reproductive Health / Obstetrics · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Gynuity Health Projects · 1 shared drug class
- Hadassah Medical Organization · 1 shared drug class
- Planned Parenthood League of Massachusetts · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Reproductive Health Training Center of the Republic of Moldova:
- Reproductive Health Training Center of the Republic of Moldova pipeline updates — RSS
- Reproductive Health Training Center of the Republic of Moldova pipeline updates — Atom
- Reproductive Health Training Center of the Republic of Moldova pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Reproductive Health Training Center of the Republic of Moldova — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reproductive-health-training-center-of-the-republic-of-moldova. Accessed 2026-05-17.